Clinically significant thrombocytopenia after TAVI occurred in 16.7% of patients, was predicted by factors including balloon-expandable valve use, and increased 2-year mortality (31.4% vs. 15.5%).
Cohort (n=342)
No
Does clinically significant thrombocytopenia after TAVI predict worse mid-term mortality in patients with severe aortic stenosis?
Clinically significant thrombocytopenia after TAVI is relatively common (16.7%) and is independently associated with significantly higher 30-day and 2-year mortality.
Absolute Event Rate: 31.4% vs 15.5%
p-value: p=0.008
BACKGROUND: The frequency and predictors of thrombocytopenia after transcatheter aortic valve implantation (TAVI) are unclear. METHODS AND RESULTS: /L (OR 2.98; 95% CI 1.20-7.38), multiple blood transfusions (OR 4.03; 95% CI 1.72-9.41), and the use of balloon-expandable valves (OR 2.38; 95% CI 1.04-5.46). Kaplan-Meier survival analysis with a generalized Wilcoxon test revealed that mid-term (2 years) mortality was greater for patients with than without CSTP (31.4% vs. 15.5%; P=0.008). CONCLUSIONS: TAVI-related CSTP was not rare and was associated with poor mid-term outcomes. CSTP was not only caused by patients' comorbidities and TAVI complications, but also related to TAVI procedural factors.
Takahashi et al. (Fri,) conducted a cohort in Symptomatic severe aortic valve stenosis (n=342). Clinically significant thrombocytopenia (CSTP) vs. No CSTP was evaluated on 2-year all-cause mortality (p=0.008). Clinically significant thrombocytopenia after TAVI occurred in 16.7% of patients, was predicted by factors including balloon-expandable valve use, and increased 2-year mortality (31.4% vs. 15.5%).